ritanserin has been researched along with Duncan Disease in 1 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Velnati, S | 1 |
| Ruffo, E | 1 |
| Massarotti, A | 1 |
| Talmon, M | 1 |
| Varma, KSS | 1 |
| Gesu, A | 1 |
| Fresu, LG | 1 |
| Snow, AL | 1 |
| Bertoni, A | 1 |
| Capello, D | 1 |
| Tron, GC | 1 |
| Graziani, A | 1 |
| Baldanzi, G | 1 |
1 other study available for ritanserin and Duncan Disease
| Article | Year |
|---|---|
Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
Topics: Cell Death; Computer Simulation; Diacylglycerol Kinase; Drug Evaluation, Preclinical; Humans; Lympho | 2019 |